BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

466 related articles for article (PubMed ID: 25172841)

  • 1. Emerging potential of therapeutic targeting of ubiquitin-specific proteases in the treatment of cancer.
    Pal A; Young MA; Donato NJ
    Cancer Res; 2014 Sep; 74(18):4955-66. PubMed ID: 25172841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deubiquitinase inhibition as a cancer therapeutic strategy.
    D'Arcy P; Wang X; Linder S
    Pharmacol Ther; 2015 Mar; 147():32-54. PubMed ID: 25444757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deubiquitinases (DUBs) and DUB inhibitors: a patent review.
    Farshi P; Deshmukh RR; Nwankwo JO; Arkwright RT; Cvek B; Liu J; Dou QP
    Expert Opin Ther Pat; 2015; 25(10):1191-1208. PubMed ID: 26077642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular pathways: translational potential of deubiquitinases as drug targets.
    D'Arcy P; Linder S
    Clin Cancer Res; 2014 Aug; 20(15):3908-14. PubMed ID: 25085788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of Ubiquitin-Specific Proteases as a Novel Anticancer Therapeutic Strategy.
    Yuan T; Yan F; Ying M; Cao J; He Q; Zhu H; Yang B
    Front Pharmacol; 2018; 9():1080. PubMed ID: 30319415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The therapeutic potential of deubiquitinating enzyme inhibitors.
    Colland F
    Biochem Soc Trans; 2010 Feb; 38(Pt 1):137-43. PubMed ID: 20074048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deubiquitinating enzyme inhibitors and their potential in cancer therapy.
    Crosas B
    Curr Cancer Drug Targets; 2014; 14(6):506-16. PubMed ID: 25088039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of proteasome deubiquitinase activity: a strategy to overcome resistance to conventional proteasome inhibitors?
    Selvaraju K; Mazurkiewicz M; Wang X; Gullbo J; Linder S; D'Arcy P
    Drug Resist Updat; 2015; 21-22():20-9. PubMed ID: 26183292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the ubiquitin pathway for cancer treatment.
    Liu J; Shaik S; Dai X; Wu Q; Zhou X; Wang Z; Wei W
    Biochim Biophys Acta; 2015 Jan; 1855(1):50-60. PubMed ID: 25481052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutically targeting the SUMOylation, Ubiquitination and Proteasome pathways as a novel anticancer strategy.
    Driscoll JJ; Dechowdhury R
    Target Oncol; 2010 Dec; 5(4):281-9. PubMed ID: 21125340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deubiquitinating enzymes as therapeutic targets in cancer.
    Lim KH; Baek KH
    Curr Pharm Des; 2013; 19(22):4039-52. PubMed ID: 23181570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of ubiquitin-specific peptidases in cancer progression.
    Young MJ; Hsu KC; Lin TE; Chang WC; Hung JJ
    J Biomed Sci; 2019 May; 26(1):42. PubMed ID: 31133011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DUBing Primary Tumors of the Central Nervous System: Regulatory Roles of Deubiquitinases.
    Klonisch T; Logue SE; Hombach-Klonisch S; Vriend J
    Biomolecules; 2023 Oct; 13(10):. PubMed ID: 37892185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in the Development Ubiquitin-Specific Peptidase (USP) Inhibitors.
    Chen S; Liu Y; Zhou H
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33925279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deubiquitinases and the new therapeutic opportunities offered to cancer.
    Pfoh R; Lacdao IK; Saridakis V
    Endocr Relat Cancer; 2015 Feb; 22(1):T35-54. PubMed ID: 25605410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of the ubiquitin proteasome system in hematologic malignancies.
    Sahasrabuddhe AA; Elenitoba-Johnson KS
    Immunol Rev; 2015 Jan; 263(1):224-39. PubMed ID: 25510280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ubiquitin-proteasome system (UPS) as a target for anticancer treatment.
    Park J; Cho J; Song EJ
    Arch Pharm Res; 2020 Nov; 43(11):1144-1161. PubMed ID: 33165832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting ubiquitin specific proteases for drug discovery.
    Daviet L; Colland F
    Biochimie; 2008 Feb; 90(2):270-83. PubMed ID: 17961905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simultaneous inhibition of deubiquitinating enzymes (DUBs) and autophagy synergistically kills breast cancer cells.
    Vogel RI; Coughlin K; Scotti A; Iizuka Y; Anchoori R; Roden RB; Marastoni M; Bazzaro M
    Oncotarget; 2015 Feb; 6(6):4159-70. PubMed ID: 25784654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteasome deubiquitinases as novel targets for cancer therapy.
    D'Arcy P; Linder S
    Int J Biochem Cell Biol; 2012 Nov; 44(11):1729-38. PubMed ID: 22819849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.